Literature DB >> 33599712

Rapid implementation of a new ambulatory infusion location for patients with COVID-19 to receive monoclonal antibody therapy.

Amy K Harris1, Anna M Gibson2, Brian Spencer1, Angela Stroud2, Gina Huhnke1, Amanda Bohleber1, Ashley Hinton3, Jenny Hurley1.   

Abstract

Entities:  

Keywords:  COVID-19; asirivimab/indevimab; bamlanivimab; casirivimab/indevimab; infusion; monoclonal antibody

Mesh：

Substances：

Year:  2021        PMID： 33599712      PMCID： PMC7929373          DOI： 10.1093/ajhp/zxab054

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  2 in total

1.  Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.

Authors:  Erin K McCreary; J Ryan Bariola; Tami Minnier; Richard J Wadas; Judith A Shovel; Debbie Albin; Oscar C Marroquin; Mark Schmidhofer; Mary Kay Wisniewski; David A Nace; Colleen Sullivan; Meredith Axe; Russell Meyers; Tina Khadem; William Garrard; Kevin Collins; Alan Wells; Robert D Bart; Kelsey Linstrum; Stephanie K Montgomery; Ghady Haidar; Graham M Snyder; Bryan J McVerry; Christopher W Seymour; Donald M Yealy; David T Huang; Derek C Angus
Journal:  Contemp Clin Trials       Date:  2021-12-09       Impact factor: 2.226

2.  Essential services: Quantifying the contributions of America's pharmacists in COVID-19 clinical interventions.

Authors:  John D Grabenstein
Journal:  J Am Pharm Assoc (2003)       Date:  2022-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.